Related Experiment Video
Updated: Aug 30, 2025

05:58
Evaluation of a Point-of-Care Testing Analyzer for Measuring Peripheral Blood Leukocytes
Published on: March 22, 2022
4.2K
Performance evaluation between two automated biochemical analyzer systems: Roche Cobas 8000 and Mindray BS2000M
Mingxing Chen1, Simeng Qin1, Sitao Yang1
1First Affiliated Hospital of Guangxi Medical University, Department of Clinical Laboratory, China.
Journal of Medical Biochemistry
|August 31, 2022
Summary
The Roche Cobas 8000 and Mindray BS2000M automated analyzers show good correlation and consistency for most biomarkers, indicating interchangeability for clinical decision-making.
Area of Science:
- Clinical Chemistry
- Biomarker Analysis
- Medical Diagnostics
Background:
- Biomarker values are crucial for clinical decisions.
- The performance of automated chemical analyzers is not well-defined.
- This study compares the Roche Cobas 8000 and Mindray BS2000M platforms.
Purpose of the Study:
- To evaluate the consistency and accuracy of biomarker measurements between two automated platforms.
- To determine if the Roche Cobas 8000 and Mindray BS2000M are interchangeable for clinical use.
Main Methods:
- 1869 serum samples were analyzed.
- Biomarkers assessed include CK, LDH-1, RBP, Cys-C, IgA, IgM, and IgG.
- Statistical analyses included paired t-test, Passing-Bablok regression, and Bland-Altman analysis.
Main Results:
- Significant differences in average bias were observed between the two machines (P<0.001).
- CK, LDH-1, Cys-C, and IgG showed no systematic error; IgM showed no measurement difference.
- High correlation (r > 0.91) and consistency were found for most biomarkers, with Bland-Altman analysis supporting interchangeability for CK, LDH-1, RBP, Cys-C, IgM, and IgG.
Conclusions:
- The Roche Cobas 8000 and Mindray BS2000M demonstrate good correlation and consistency for CK, LDH-1, RBP, Cys-C, IgM, and IgG.
- These two automated analyzers are considered interchangeable for clinical applications.
- The findings support the use of either platform for routine biomarker assessment.

